Jefferies Group LLC reissued their underperform rating on shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) in a report issued on Thursday. They currently have a $7.00 price target on the biopharmaceutical company’s stock, up from their prior price target of $6.75. Jefferies Group also issued estimates for Halozyme Therapeutics’ Q3 2017 earnings at ($0.27) EPS, Q4 2017 earnings at ($0.26) EPS, FY2017 earnings at ($1.01) EPS, FY2019 earnings at ($0.58) EPS, FY2020 earnings at ($0.40) EPS and FY2021 earnings at ($0.13) EPS.

Other research analysts also recently issued research reports about the company. BMO Capital Markets began coverage on Halozyme Therapeutics in a research note on Monday, April 17th. They set a market perform rating and a $14.00 price target on the stock. Canaccord Genuity set a $16.00 target price on Halozyme Therapeutics and gave the company a buy rating in a research note on Wednesday, July 26th. ValuEngine upgraded Halozyme Therapeutics from a sell rating to a hold rating in a research note on Friday, June 2nd. BidaskClub downgraded Halozyme Therapeutics from a buy rating to a hold rating in a research note on Saturday, July 1st. Finally, Barclays PLC reiterated an overweight rating and issued a $16.00 target price on shares of Halozyme Therapeutics in a research note on Friday, June 23rd. One investment analyst has rated the stock with a sell rating, four have given a hold rating and six have issued a buy rating to the company. Halozyme Therapeutics presently has an average rating of Hold and a consensus price target of $14.75.

Shares of Halozyme Therapeutics (NASDAQ HALO) traded down 1.90% on Thursday, reaching $11.90. The company’s stock had a trading volume of 865,040 shares. The company’s market capitalization is $1.59 billion. The stock has a 50-day moving average price of $13.12 and a 200-day moving average price of $13.12. Halozyme Therapeutics has a 1-year low of $8.18 and a 1-year high of $15.20.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.02. The firm had revenue of $33.80 million for the quarter, compared to analysts’ expectations of $31.76 million. The company’s quarterly revenue was up 1.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.21) EPS. On average, equities research analysts forecast that Halozyme Therapeutics will post ($0.97) EPS for the current year.

WARNING: This article was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another publication, it was illegally copied and republished in violation of US & international copyright & trademark law. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/08/13/halozyme-therapeutics-inc-nasdaqhalo-earns-underperform-rating-from-jefferies-group-llc.html.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. IFP Advisors Inc increased its position in shares of Halozyme Therapeutics by 1.6% in the second quarter. IFP Advisors Inc now owns 14,686 shares of the biopharmaceutical company’s stock valued at $188,000 after buying an additional 226 shares during the period. ProShare Advisors LLC boosted its stake in Halozyme Therapeutics by 0.5% in the second quarter. ProShare Advisors LLC now owns 82,187 shares of the biopharmaceutical company’s stock valued at $1,054,000 after buying an additional 374 shares in the last quarter. Principal Financial Group Inc. boosted its stake in Halozyme Therapeutics by 2.8% in the first quarter. Principal Financial Group Inc. now owns 20,602 shares of the biopharmaceutical company’s stock valued at $267,000 after buying an additional 558 shares in the last quarter. IFC Holdings Incorporated FL boosted its stake in Halozyme Therapeutics by 0.7% in the first quarter. IFC Holdings Incorporated FL now owns 82,250 shares of the biopharmaceutical company’s stock valued at $1,063,000 after buying an additional 600 shares in the last quarter. Finally, Amalgamated Bank boosted its stake in Halozyme Therapeutics by 5.3% in the second quarter. Amalgamated Bank now owns 14,067 shares of the biopharmaceutical company’s stock valued at $180,000 after buying an additional 705 shares in the last quarter. Institutional investors own 81.49% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.

Analyst Recommendations for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Stock Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related stocks with our FREE daily email newsletter.